Dr. Naiem Issa shares real-world evidence showing how ruxolitinib cream may reduce treatment costs and productivity loss in patients with atopic dermatitis. Topics Covered: Economic
Dr. Diego Ruiz Dasilva highlights real-world data showing oral JAK inhibitors can safely and effectively achieve treatment targets in elderly patients with AD. Topics Covered:
Dr. Lisa Swanson shares insights on maximum-use data for ruxolitinib cream in children ages 2–11 with atopic dermatitis, highlighting safety and efficacy. Topics Covered: Ruxolitinib
Lisa Swanson, MD, JCAD’s Section Editor of Pediatric Dermatology, shares her thoughts on new research evaluating maximum-use conditions for topical ruxolitinib cream in pediatric patients
Dr. Michael Cameron discusses 52-week results showing rapid and lasting improvements in itch and quality of life with upadacitinib plus topical steroids. Topics Covered: Combination
Dr. James Song highlights the need for personalized approaches in atopic dermatitis care to predict treatment response and reduce trial-and-error prescribing. Topics Covered: Personalization in
Dr. James Song reviews the latest long-term safety data on topical and oral JAK inhibitors for managing atopic dermatitis**.** Topics Covered: Long-term safety of JAK
Melodie Young, MSN, RN, ANP-C, discusses treating young children with atopic dermatitis and counseling caregivers on potential side effects. Topics Covered: Pediatric atopic dermatitis treatment
